A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kawamoto, Megumi ^a   Horibe, Tomohisa ^a   Kohno, Masayuki ^a,b   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Upstream Infinity Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; HYBRID PROTEIN; LIPOCORTIN 5; PEPTIDE DERIVATIVE; PROTEIN ANTIBODY; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; IMMUNOTOXIN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL MEMBRANE; CHEMOSENSITIVITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; ENZYME ACTIVITY; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE DAMAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; SUBCUTANEOUS TISSUE TUMOR; AMINO ACID SEQUENCE; ANIMAL; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENETICS; KIDNEY; LIVER; METABOLISM; MOLECULAR GENETICS; NEOPLASM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SPLEEN; TIME; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; FEMALE; HUMANS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; KIDNEY; LIVER; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES; PROTEIN BINDING; RECEPTORS, TRANSFERRIN; RNA INTERFERENCE; SPLEEN; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051784652     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-359     Document Type: Article

References (50)

1. Neckers LM, Trepel JB. Transferrin receptor expression and the control of cell growth. Cancer Invest 1986, 4:461-470. 10.3109/07357908609017524, 3026588.
2. Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999, 31:1111-1137. 10.1016/S1357-2725(99)00070-9, 10582342.
3. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1997, 1331:1-40.
4. Omary MB, Trowbridge IS, Minowada J. Human cell surface glycoprotein with unusual properties. Nature 1980, 286:888-91. 10.1038/286888a0, 7412870.
5. Sutherland R, Delia D, Schneider C, Newman R, Kemshead J, Greaves M. Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferring. Proc Natl Acad Sci USA 1981, 78:4515-4519. 10.1073/pnas.78.7.4515, 319822, 6270680.
6. Shindelman JE, Ortmeyer AE, Sussman HH. Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 1981, 27:329-334. 10.1002/ijc.2910270311, 6270015.
7. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983, 36:539-54. 10.1136/jcp.36.5.539, 498283, 6302135.
8. Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet 1983, 1:498-501.
9. Kondo K, Noguchi M, Mukai Z, Matsuno Y, Sato Y, Shimosato Y, Monden Y. Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest 1990, 97:1367-1371. 10.1378/chest.97.6.1367, 2189695.
10. Walker RA, Day SJ. Transferrin receptor expression in nonmalignant and malignant human breast tissue. J Pathol 1986, 148:217-224. 10.1002/path.1711480305, 3009766.
11. Seymour GJ, Walsh MD, Lavin MF, Strutton G, Gardiner RA. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res 1987, 15:341-344.
12. Yang DC, Wang F, Elliott RL, Head JF. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res 2001, 21:541-549.
13. Prior R, Reifenberger G, Wechsler W. Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol 1990, 416:491-496. 10.1007/BF01600299, 2110696.
14. Das Gupta A, Shah VI. Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Hematol Pathol 1990, 4:37-41.
15. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006, 121:144-158. 10.1016/j.clim.2006.06.010, 16904380.
16. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta 1997, 1333:C1-C6.
17. Krietman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006, 8:E532-551. 10.1208/aapsj080363, 2761061, 17025272.
18. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000, 6:2157-2165.
19. Cintredekin Besudotox Intraparenchymal Study Group Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007, 25:837-844. 10.1200/JCO.2006.08.1117, 17327604, Cintredekin Besudotox Intraparenchymal Study Group.
20. Foss FM. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000, 2:110-117.
21. Piascik P. FDA approves fusion protein for treatment of lymphoma. J Am Pharm Assoc 1999, 39:571-572.
22. Frankel AE. Reducing the Immune Response to Immunotoxin Commentary re R. Hassan et al. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 2004, 10:16-18. 10.1158/1078-0432.CCR-1160-3, 14734446.
23. Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DT-GM, a novel fusion toxin consisting of truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colonystimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol 2001, 100:191-197. 10.1006/clim.2001.5066, 11465948.
24. Hertler AA, Spitler LE, Frankel AE. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Deliv 1987, 4:245-253. 10.1089/cdd.1987.4.245, 3502618.
25. Papo N, Shai Y. New lytic peptides based on the D, L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 2003, 42:9346-9354. 10.1021/bi027212o, 12899621.
26. Kohno M, Horibe T, Haramoto M, Yano Y, Ohara K, Nakajima O, Matsuzaki K, Kawakami K. A novel hybrid peptide targeting EGFR-expressing cancers. Eur J Cancer 2011, 47:773-783. 10.1016/j.ejca.2010.10.021, 21112771.
27. Lee JH, Engler JA, Collawn JF, Moore BAJ. Rceptor mediated uptake of peptides that bind the human transferrinreceptor. Eur J Biochem 2001, 268:2004-2012. 10.1046/j.1432-1327.2001.02073.x, 11277922.
28. Lien S, Lowman HB. Therapeutic peptides. Trends Biotechnol 2003, 21:556-562. 10.1016/j.tibtech.2003.10.005, 14624865.
29. Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, Löbel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 2006, 66:811-821. 10.1002/pros.20404, 16482569.
30. Chromek M, Slamová Z, Bergman P, Kovács L, Podracká L, Ehrén I, Hökfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 2006, 12:636-641. 10.1038/nm1407, 16751768.
31. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-43. 10.1038/nature05901, 17572664.
32. Wark PA. DX-890 (Dyax). IDrugs 2002, 5:586-589.
33. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999, 5:1032-1038. 10.1038/12469, 10470080.
34. Haynes BF, Hemler M, Cotner T, Mann DL, Eisenbarth GS, Strominger JL, Fauci AS. Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. J Immunol 1981, 127:347-351.
35. Goding JW, Burns GF. Monoclonal antibody OKT-9 recognizes the receptor for transferrin on human acute lymphocytic leukemia cells. J Immunol 1981, 127:1256-1258.
36. Trowbridge IS. Transferrin receptor as a potential therapeutic target. Prog Allergy 1988, 45:121-146.
37. Peng JL, Wu S, Zhao XP, Wang M, Li WH, Shen X, Liu J, Lei P, Zhu HF, Shen GX. Downregulation of transferrin receptor surface expression by intracellular antibody. Biochem Biophys Res Commun 2007, 354:864-71. 10.1016/j.bbrc.2007.01.052, 17266924.
38. Trowbridge IS, Domingo DL. Anti-transferrin receptormonoclonal antibody and toxinantibody conjugates affect growth of human tumor cells. Nature 1981, 294:171-173. 10.1038/294171a0, 6272120.
39. Kemp JD, Thorson JA, McAlmont TH, Horowitz M, Cowdery JS, Ballas ZK. Role of the transferring receptor in lymphocyte growth: a rat IgG monoclonal antibody against the murine transferrin receptor produces highly selective inhibition of T and B cell activation protocols. J Immunol 1987, 138:2422-2426.
40. Trowbridge IS, Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cells growth in vitro. Proc Natl Acad Sci USA 1982, 79:1175-1179. 10.1073/pnas.79.4.1175, 345924, 6280171.
41. Lesley JF, Schulte RJ. Inhibition of cell growth by monoclonal anti-transferrin receptor antibodies. Mol Cell Biol 1985, 5:1814-1821. 366896, 3018527.
42. Lesley J, Schulte R, Woods J. Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments. Exp Cell Res 1989, 182:215-233. 10.1016/0014-4827(89)90293-0, 2653853.
43. Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecularevents contributing to cell death inmalignant human hematopoietic cells elicited by an IgG3- avidin fusion protein targeting the transferrin receptor. Blood 2006, 108:2745-2754. 10.1182/blood-2006-04-020263, 1895578, 16804109.
44. Moura IC, Lepelletier Y, Arnulf B, England P, Baude C, Beaumont C, Bazarbachi A, Benhamou M, Monteiro RC, Hermine O. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 2004, 103:1838-1845. 10.1182/blood-2003-07-2440, 14592824.
45. Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML. An antitransferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci USA 2002, 99:10706-10711. 10.1073/pnas.162362999, 125019, 12149472.
46. Papo N, Braunstein A, Eshhar Z, Shai Y. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res 2004, 64:5779-5786. 10.1158/0008-5472.CAN-04-1438, 15313920.
47. Papo N, Seger D, Makovitzki A, Kalchenko V, Eshhar Z, Degani H, Shai Y. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res 2006, 66:5371-5378. 10.1158/0008-5472.CAN-05-4569, 16707464.
48. Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, Kornfeld S, Taetle R. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin Cancer Res 1995, 1:1259-1265.
49. Laske DW, Muraszko KM, Oldfield EH, DeVroom HL, Sung C, Dedrick RL, Simon TR, Colandrea J, Copeland C, Katz D, Greenfield L, Groves ES, Houston LL, Youle RJ. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 1997, 41:1039-1049. 10.1097/00006123-199711000-00005, 9361057.
50. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neuro oncol 2003, 65:3-13.